Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
PATH-2 logo

THE PATH-2 Study is a trial of platelet rich plasma (PRP) as a non-surgical treatment for Achilles tendon rupture. PRP is blood plasma containing a high concentration of platelets, specialised blood cells involved in wound repair. Eligible patients are randomised to receive standard non-operative care, or standard care plus PRP injection. Our primary outcome is an objective test of ankle function conducted at 6 months after treatment by a blinded physiotherapist assessor. This is the first large double-blinded randomised controlled trial of PRP in tendons.

In September 2017 the PATH-2 Study reached its target of 230 participants, recruited at outpatient clinics in 18 hospitals in England and Wales. PATH-2 is funded by EME, a partnership of the National Institute for Health Research and the Medical Research Council (EME reference 12/206/30).

For more information visit https://path2.octru.ox.ac.uk/ or contact the team at path-2.study@ndorms.ox.ac.uk.

Similar stories

SCIENCE spreads across the world

Oxford Trauma are pleased to open their first overseas site for the SCIENCE study.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.

PRoCuRe opens to recruitment

The Partial Rotator Cuff Tear Repair Trial (PRoCuRe) is open to recruitment at Oxford University Hospitals NHS Foundation Trust after achieving OCTRU Green Light approval!

IMP-MEL Trial given Green Light to open

OCTRU have now given Green Light approval for IMP MEL to open. This is a phase 1 first-in-human dose finding/randomised phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC.

WISE opens to recruitment

The WISE Study - Wrist Injury Strengthening Exercise: a randomised multicentre feasibility study of resistance exercise versus usual care for optimising function after distal radius fracture in adults aged 50 years or over has now received OCTRU Green Light approval and has opened to recruitment.